Targeted radionuclide therapy of human tumors

Sergey V. Gudkov*, Natalya Yu Shilyagina, Vladimir A. Vodeneev, Andrei V. Zvyagin

*Corresponding author for this work

Research output: Contribution to journalReview article

37 Citations (Scopus)
35 Downloads (Pure)

Abstract

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.

Original languageEnglish
Article number33
Pages (from-to)1-19
Number of pages19
JournalInternational Journal of Molecular Sciences
Volume17
Issue number1
DOIs
Publication statusPublished - 2016

    Fingerprint

Bibliographical note

Copyright 2015 by the authors; licensee MDPI, Basel, Switzerland. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Antibody
  • Auger electron
  • Peptide
  • Radio-immunotherapy
  • Radionuclide
  • Targeted therapy
  • α-emitter
  • β-emitter

Cite this